Related Experiment Video

Updated: Jun 27, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Therapeutic trials for systemic sclerosis: an update

Kabir Sardana1, V K Garg

  • 1Department of Dermatology, Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India. kabirijdvl@gmail.com

Indian Journal of Dermatology, Venereology and Leprology
|December 5, 2008
PubMed

Insights

Systemic sclerosis (SSc) pathogenesis remains complex, complicating clinical trials. Early diagnosis and identifying patients for aggressive treatment are crucial for better outcomes in this autoimmune disease.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) exhibits complex pathogenesis, with ongoing research to fully elucidate its mechanisms.
  • The disease presents significant clinical heterogeneity, diverse autoimmune profiles, and a variable disease course, including spontaneous remission, posing challenges for therapeutic development.

Purpose of the Study:

  • To review data from recent clinical trials in systemic sclerosis.
  • To derive lessons from these trials to improve future research and patient management.

Main Methods:

  • Review of existing clinical trial data for systemic sclerosis.
  • Analysis of challenges and successes in SSc clinical trial design.

Main Results:

  • Clinical trial design in SSc is hindered by disease heterogeneity and unpredictable course.
  • Identifying patients who will benefit from early, aggressive treatment is a key unmet need.

Conclusions:

  • Early diagnosis and targeted treatment strategies are paramount for improving outcomes in systemic sclerosis.
  • Lessons learned from past clinical trials are essential for advancing SSc research and therapy.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...